Baxter, a pharmaceutical company, has notched another mark on its list of corruption scandals. It is now Chile, where the National Economic Prosecutor’s Office (FNE) accuses Mexico’s drugmaker Jaime Alberto Upegui of colluding with another laboratory to jointly award a tender for saline sodium chloride, one of the most commonly used medical supplies in health centers. Both laboratories agreed among themselves to submit proposals to sell above market costs.
This illegal agreement, apparently orchestrated by senior Baxter executives, affected the National Center for Supply of the National Health Services System (Cenabast) and the Concepción Regional Hospital for more than 460 million Chilean pesos (US $700,000 aprox.).
To the list of cases of international corruption of this firm is added a pending judgment in the United States for practices of unfair trade, retaining intravenous solutions to create artificial demand in the market and then increase their prices by up to three hundred percent.
Full Content: Crónica
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Subscribers Defend $4.7 Billion Antitrust Verdict Against NFL in Court Filings
Jul 19, 2024 by
CPI
Von der Leyen Calls for Competition Policy to Boost EU Companies’ Growth
Jul 19, 2024 by
CPI
Vermont AG Sues Pharmacy Benefit Managers Over Drug Prices
Jul 18, 2024 by
CPI
Australians Face Increased Stamp Prices Following ACCC Approval
Jul 18, 2024 by
CPI
Live Nation Seeks Dismissal of DOJ Antitrust Allegations
Jul 18, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Private Equity Roll-Up Schemes
Jun 28, 2024 by
CPI
The FTC’s Focus on Private Equity is Warranted
Jun 28, 2024 by
CPI
Unraveling the Roll-Up: Private Equity’s Misunderstood Investment Strategy
Jun 28, 2024 by
CPI
Antitrust Focus on Private Equity Funds and Serial Acquisitions
Jun 28, 2024 by
CPI
Private Equity Roll-Ups Amidst Heightened Antitrust Enforcement
Jun 28, 2024 by
CPI